Pelican

Pelican Therapeutics is a biotechnology company focused on developing next-generation immuno-oncology therapies that target the Tumor Necrosis Factor Receptor Superfamily (TNFRSF). The company's lead program, PTX-35, is a functional antibody agonist of the OX40 receptor designed to enhance the proliferation and survival of antigen-specific T cells. By leveraging its expertise in T-cell costimulation, Pelican aims to provide durable clinical responses in patients with various solid tumors. The company was acquired by Heat Biologics (now NightHawk Biosciences) to integrate its agonist pipeline with Heat's existing T-cell activation platforms.